Gastric Cancer
Advertisement
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Patients with locally advanced GC who achieved pCR after NAC had significantly better survival outcomes.
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
A recent study reviewed global disparities in gastric cancer screening, finding limited research about screening feasibility.
Tislelizumab is a monoclonal antibody with a high affinity and binding specificity against programmed cell death protein 1.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
A recent study utilized patient data from 13 medical centers in a biomarker analysis of 1L ICIs with & without ...
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.